Skip to content

Evaluation of the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens

Evaluation of the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00537875
Enrollment
36
Registered
2007-10-02
Start date
2007-09-30
Completion date
2009-09-30
Last updated
2015-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nausea, Vomiting

Brief summary

The purpose of this study is to determine whether powdered ginger root (encapsulated ginger) is effective for reducing the frequency, duration and severity of both acute and delayed nausea and vomiting.

Interventions

DIETARY_SUPPLEMENTGinger

Capsule, 1000 mg, BID, 3 days

DIETARY_SUPPLEMENTPlacebo

Capsule, 1000 mg, BID, 3 days

Sponsors

National Research Institute of Tuberculosis and Lung Disease, Iran
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Must be able to give written informed consent. * Have a diagnosis of cancer and currently receiving chemotherapy containing cisplatin (any dose). * Scheduled to receive antiemetics: granisetron (kytril), hydrocortisone. * Must be able to complete study questionnaires. * Must be able to swallow capsules.

Exclusion criteria

* Have no clinical evidence of current or impending bowel obstruction. * Concurrent radiotherapy that is classified as high or intermediate risk of causing emesis. * Pregnant or lactating. * Patients taking therapeutic doses of coumadin (individuals on low-dose to maintain peripheral or central venous catheters are allowed), aspirin (individuals taking low-dose 80mg aspirin are allowed), or heparin. * Patients with a history of a bleeding disorder(s) in past 6 months and those experiencing thrombocytopenia.

Design outcomes

Primary

MeasureTime frame
Nausea, Vomiting3 days

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026